Company intelligence / Profile preview

Intarcia Therapeutics

Boston, Massachusetts, United Statesen.wikipedia.org ↗

Ownership: Private
Employees: ~76
Development stage: Phase 3

Overview

Intarcia developed ITCA 650, an implantable device that delivers exenatide for type 2 diabetes treatment. The FDA rejected applications in 2017 and 2020, with a third attempt and advisory committee meeting scheduled for September 21, 2023. The company was acquired by i2o Therapeutics in 2023.

Therapeutic areas: ImmunologyEndocrinologyInfectious Diseases
Modalities: Therapeutic proteinspeptidesGLP-1 receptor agonists
Industry: Biotech

Drug pipeline

4 assets

ITCA 650

3 more assets in the full pipeline.

Request access →

Partnerships

Harvard University (through i2o)

Beyond the preview

Go deeper on Intarcia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intarcia Therapeutics.

Explore the full profile